阿尔茨海默病中的淋巴系统损伤:与周血管空间体积和认知功能的关联
Xue Zhang1,2, Yue Wang3,4,5, Bingjie Jiao6
1Tiantan Neuroimaging Center of Excellence, China National Clinical Research Center for Neurological Diseases, Fengtai District, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Beijing, China.
European radiology
|August 23, 2023
概括
患有阿尔茨海默氏症痴呆症的患者有淋巴功能受损,通过沿周围血管空间 (DTI-ALPS) 指数的较低扩散张力图像分析来表明. 这一DTI-ALPS指数与周血管空间扩大和认知能力下降有关.
科学领域:
- 神经成像是一种神经成像.
- 神经退行性疾病 神经退行性疾病
- 脑血管生物学 脑血管生物学
背景情况:
- 淋巴系统功能障碍与阿尔茨海默病 (AD) 病理生理学有关.
- 沿周血管空间进行扩散张力图像分析 (DTI-ALPS) 是评估淋巴功能的一种新方法.
- 在AD中,DTI-ALPS,周血管空间 (PVS) 体积和认知状态之间的关系需要进一步调查.
研究的目的:
- 用DTI-ALPS方法评估阿尔茨海默病 (AD) 痴呆症中的淋巴功能.
- 探索DTI-ALPS指数和PVS体积之间的关联.
- 检查AD患者的DTI-ALPS指数和认知表现之间的相关性.
主要方法:
- 招募了30名确诊患有AD (痴呆症或MCI) 的患者和26名健康对照 (NCs).
- 获得神经学MRI并进行认知评估.
- 计算双边DTI-ALPS指数和测量PVS体积分数在基底,半圆中心和侧腔室水平.
主要成果:
- 与NCs相比,AD痴呆症患者的整脑和左半球DTI-ALPS指数明显较低.
- 基底质PVS体积分数在阿兹海默症患者中较大,与DTI-ALPS指数负相关.
- 较低的DTI-ALPS指数与波士顿命名测试,步道制作测试A和数字跨度测试的表现较差相关.
结论:
- 在AD痴呆症中降低的DTI-ALPS指数表明淋巴系统功能受损.
- DTI-ALPS指数与基底腺PVS扩大和特定领域的认知缺陷有关.
- 在阿尔茨海默病中,DTI-ALPS可以作为评估淋巴系统完整性的宝贵生物标志物.
相关概念视频
Alzheimer's Disease: Overview
518
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
518
Alzheimer's Disease: Treatment
213
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
213


